ArticleScientific reports2019
Rational Identification of a Colorectal Cancer Targeting Peptide through Phage Display.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Selection of aptamers against triple negative breast cancer cells using high throughput sequencing.Scientific reports · 2021Trial
- Identification of novel human IgE-binding peptides from a phage display library for total IgE detection.Scientific reports · 2025Article
- Phage display technology in ecotoxicology: phage display derived unique peptide for copper identification in aquatic samples.Microbial cell factories · 2025Article
- B cells present a double-sided effect in digestive system tumors: a review for tumor microenvironment.Translational gastroenterology and hepatology · 2024Review
- The Biotechnological Application of Bacteriophages: What to Do and Where to Go in the Middle of the Post-Antibiotic Era.Microorganisms · 2023Review
- The Use of Peptides in Veterinary Serodiagnosis of Infectious Diseases: A Review.Veterinary sciences · 2022Review
- Overcoming the cellular barriers and beyond: Recent progress on cell penetrating peptide modified nanomedicine in combating physiological and pathological barriers.Asian journal of pharmaceutical sciences · 2022Review
- An auto-antibody identified from phenotypic directed screening platform shows host immunity against EV-A71 infection.Journal of biomedical science · 2022Article
- New Developments and Opportunities of Microbiota in Treating Breast Cancers.Frontiers in microbiology · 2022Review
- Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy.International journal of peptide research and therapeutics · 2021Review
- Nanocomplexes loaded with miR-128-3p for enhancing chemotherapy effect of colorectal cancer through dual-targeting silence the activity of PI3K/AKT and MEK/ERK pathway.Drug delivery · 2020Article
- Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment.Molecules (Basel, Switzerland) · 2020Review
- A Dodecapeptide Selected by Phage Display as a Potential Theranostic Probe for Colon Cancers.Translational oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer is frequently diagnosed at an advanced stage due to the absence of early clinical indicators. Hence, the identification of new targeting molecules is crucial for an early detection and development of targeted therapies. This study aimed to identify and characterize novel peptides specific for the colorectal cancer cell line RKO using a phage-displayed peptide library. After four rounds of selection plus a negative step with normal colorectal cells, CCD-841-CoN, there was an obvious phage enrichment that specifically bound to RKO cells. Cell-based enzyme-linked immunosorbent assay (ELISA) was performed to assess the most specific peptides leading to the selection of the peptide sequence CPKSNNGVC. Through fluorescence microscopy and cytometry, the synthetic peptide RKOpep was shown to specifically bind to RKO cells, as well as to other human colorectal cancer cells including Caco-2, HCT 116 and HCT-15, but not to the normal non-cancer cells. Moreover, it was shown that RKOpep specifically targeted human colorectal cancer cell tissues. A bioinformatics analysis suggested that the RKOpep targets the monocarboxylate transporter 1, which has been implicated in colorectal cancer progression and prognosis, proven through gene knockdown approaches and shown by immunocytochemistry co-localization studies. The peptide herein identified can be a potential candidate for targeted therapies for colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.